Guardian

NHS England to offer weight-loss drugs to 1.2m people to reduce risk of heart attacks and strokes

Daily Mail

Weight-loss jabs to be given to 1.2m heart patients on the NHS in major treatment shift

The Telegraph

NHS to give fat jabs to 1.2m patients to stop heart attacks

Independent

More than one million people to get ‘life-changing’ weight loss drugs to prevent heart attacks and strokes

NHS England

Over a million people could be offered Wegovy to cut heart attack and stroke risk on the NHS

Nice

Injection for more than a million people to help prevent heart attacks and strokes recommended

Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

London Hormone Clinic

Weight-loss drugs, like Ozempic, arent for everyone  London Hormone Clinic

Weight-loss drugs aren't a magic bullet. Lifestyle changes are key to lasting health

Metaculus

Oral Semaglutide Approval by 2027

The NHS in England is set to offer semaglutide, sold under the brand name Wegovy, to around 1.2 million people with cardiovascular disease to reduce their risk of heart attacks and strokes.

The NHS in England is set to offer semaglutide, sold under the brand name Wegovy, to around 1.2 million people with cardiovascular disease to reduce their risk of heart attacks and strokes.

The National Institute for Health and Care Excellence approved the weekly injection for adults with a BMI of 27 or above who have previously had a heart attack, stroke or peripheral arterial disease. The drug will be prescribed alongside statins, a reduced-calorie diet and increased physical activity.

The National Institute for Health and Care Excellence approved the weekly injection for adults with a BMI of 27 or above who have previously had a heart attack, stroke or peripheral arterial disease. The drug will be prescribed alongside statins, a reduced-calorie diet and increased physical activity.

Clinical trial data from the SELECT study, which enrolled 17,604 people, found that semaglutide reduced the risk of a major cardiovascular event — such as a heart attack, stroke or cardiovascular death — by 20% compared with a placebo.

Clinical trial data from the SELECT study, which enrolled 17,604 people, found that semaglutide reduced the risk of a major cardiovascular event — such as a heart attack, stroke or cardiovascular death — by 20% compared with a placebo.

Researchers found the cardiovascular benefit of semaglutide appeared early in the trial, before significant weight loss occurred, suggesting the drug acts directly on the heart and blood vessels rather than solely through weight reduction.

Researchers found the cardiovascular benefit of semaglutide appeared early in the trial, before significant weight loss occurred, suggesting the drug acts directly on the heart and blood vessels rather than solely through weight reduction.

Health Minister Sharon Hodgson said weight-loss drugs are "a game changer in tackling obesity" and that extending their use to people with cardiovascular disease "will be a life saver." The NHS rollout is expected to begin within months.

Health Minister Sharon Hodgson said weight-loss drugs are "a game changer in tackling obesity" and that extending their use to people with cardiovascular disease "will be a life saver." The NHS rollout is expected to begin within months.

Prof. Riyaz Patel of University College London welcomed the decision but raised concerns about NHS capacity and equitable access, warning the rollout "must not become another example where access depends on where you live."

Prof. Riyaz Patel of University College London welcomed the decision but raised concerns about NHS capacity and equitable access, warning the rollout "must not become another example where access depends on where you live."

NHS to Offer Wegovy to 1.2M Heart Disease Patients

NHS to Offer Wegovy to 1.2M Heart Disease Patients

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

NHS to Offer Wegovy to 1.2M Heart Disease Patients

NHS to Offer Wegovy to 1.2M Heart Disease Patients

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters